Peptide and compounding law · Updated
Is GHK-Cu legal?
It depends on the product. A skin-care product with copper peptides is regulated as a cosmetic as long as it is sold for appearance only; claims to treat a condition or change how the body works can make it a drug. GHK-Cu is not an FDA-approved drug and is not on the 503A bulks list, but since May 14, 2026 the FDA has listed "GHK-Cu (except for injectable routes of administration)" in Category 1 of its interim 503A policy, so it does not intend to act against a pharmacy compounding with it under that policy's conditions. Injectable GHK-Cu is not covered: it sits in the FDA's "nominated but withdrawn" table, and it is not among the six peptides in HHS's October 30, 2026 draft policy.
| Product | Federal status | Source |
|---|---|---|
| Skin-care product with copper peptides, sold with appearance claims only | Cosmetic. No FDA premarket approval (color additives aside) | 21 U.S.C. 321(i); FDA |
| The same product claiming to treat a condition or change the body's structure or function, such as "restore hair growth" | Can be a drug, and then needs to meet the drug rules | FDA, cosmetic or drug |
| Compounded GHK-Cu, other than injectable, from a 503A pharmacy on a patient-specific prescription | Category 1 of the FDA's 503A interim policy since May 14, 2026: the FDA does not intend to take action if the guidance's conditions are met | FDA 503A category list, updated May 14, 2026 |
| Compounded injectable GHK-Cu | Not in Category 1. Listed in the FDA's "nominated but withdrawn" table with a safety statement | FDA safety-risk page |
| HHS's October 30, 2026 draft peptide policy | Does not list GHK-Cu | HHS policy, Appendix A |
| GHK-Cu sold "for research use only" to people who will use it | Unapproved new drug when the seller's site shows human use | 21 CFR 201.128 |
| Date | What happened | Source |
|---|---|---|
| April 1, 2020 | FDA warning letter to a Kentucky compounding pharmacy names GHK-Cu among the substances it compounded | FDA warning letter |
| September 29, 2023 | FDA places GHK-Cu for injectable routes in Category 2 (significant safety risks) | FDA safety-risk page |
| April 22, 2026 | Nominations withdrawn: FDA removes non-injectable GHK-Cu from Category 1 and moves injectable GHK-Cu to the "nominated but withdrawn" table | FDA 503A category list; FDA safety-risk page |
| May 5, 2026 | One nominator clarifies it meant to withdraw only its nomination for the injectable route | FDA 503A category list |
| May 14, 2026 | FDA puts GHK-Cu (except for injectable routes of administration) back in Category 1 | FDA 503A category list |
| October 30, 2026 | HHS's draft peptide policy lists six peptides; GHK-Cu is not one of them | 91 FR 68526 |
| By the end of February 2027 | FDA intends to consult its Pharmacy Compounding Advisory Committee on listing GHK-Cu | FDA 503A category list |
Three products, three answers
GHK-Cu, often called copper peptide, is sold in three very different ways: in skin-care products, as a compounded drug prescribed through a clinic, and as a "research" vial online. Federal law does not regulate the molecule; it regulates the product, and what decides the category is the product's intended use (21 CFR 201.128). So the same ingredient can be a lawful cosmetic, a drug compounded under an FDA policy, or an unapproved new drug.
Copper peptides in skin care: cosmetic or drug?
A cosmetic is an article meant to be applied to the body "for cleansing, beautifying, promoting attractiveness, or altering the appearance" (21 U.S.C. 321(i)). A drug includes articles meant to treat or prevent disease, or "intended to affect the structure or any function of the body" (21 U.S.C. 321(g)(1)). The FDA says it judges intended use from the product's claims in labeling, advertising and online, from consumer perception, and from ingredients with a well-known therapeutic use, and gives claims to "restore hair growth" or "regenerate cells" as examples that make a product a drug (FDA).
Cosmetic products and ingredients, other than color additives, do not need FDA approval before they are sold (FDA). In our reading, a copper-peptide serum sold with appearance claims only is a cosmetic. The same serum marketed to regrow hair or to regenerate skin cells can be a drug, and a new drug needs FDA approval before it is shipped across state lines (21 U.S.C. 355(a)). For a brand or a med spa selling its own line, the claims on the label, the website and social media are the legal issue.
Compounded GHK-Cu: back in Category 1, except injections
A 503A pharmacy may compound only from an ingredient with a USP or National Formulary monograph, a component of an approved drug, or an ingredient on the 503A bulks list (21 U.S.C. 353a(b)(1)(A)). GHK-Cu is not on that list, which at 21 CFR 216.23 has six substances and no peptides. While the list is built, the FDA's interim policy sorts nominated substances into categories, and the FDA says it "does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met" (FDA 503A page). Bulk ingredients must come from an FDA-registered manufacturer with a valid certificate of analysis, and compounding is limited to state-licensed pharmacists and physicians.
GHK-Cu dropped out of Category 1 on April 22, 2026, when its nominations were withdrawn. On May 5, 2026 one nominator told the FDA it had meant to withdraw only its nomination for the injectable route, and the FDA's list updated May 14, 2026 says "GHK-Cu (except for injectable routes of administration) will be added back to category 1" (FDA 503A category list).
Category 1 is a statement of enforcement policy, not a listing, and the FDA can change it. The same FDA document says the agency "intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list". A listing would still take rulemaking.
Injectable GHK-Cu
Injectable GHK-Cu is outside the Category 1 entry. It was in Category 2 from September 29, 2023 and has been in the FDA's "nominated but withdrawn" table since April 22, 2026, where the FDA's entry reads: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations" (FDA safety-risk page).
GHK-Cu is also not among the six peptides in Appendix A of HHS's October 30, 2026 draft enforcement policy, which lists BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 (HHS policy). As of November 2, 2026 we have found no federal policy that covers compounding injectable GHK-Cu. Outsourcing facilities work from separate 503B lists and categories; a clinic buying office stock should check the substance on the FDA's 503B category list and see 503A vs 503B.
Research-use-only GHK-Cu and enforcement
A "research use only" label does not settle intended use; the FDA looks at labeling, advertising and "the circumstances surrounding the distribution" (21 CFR 201.128). Selling GHK-Cu vials to people who will inject them is, in the FDA's view, selling an unapproved new drug. More in Research-use-only peptides.
GHK-Cu has appeared in federal cases. The FDA's 2020 warning letter to a Kentucky compounding pharmacy named GHK-Cu among the substances it compounded (FDA), and the April 2026 indictment of a Utah physician lists GHK and GHK-CU among the peptides he allegedly obtained from China and sold to patients (DOJ, D. Utah). An indictment is an allegation, not a finding of guilt.
North Carolina
North Carolina's Board of Pharmacy lets a pharmacy dispense a compounded drug only on a valid prescription, bars offering compounded drugs to others for resale, and allows office-use compounding only as federal law permits (21 NCAC 46 .2801). A med spa that sells a copper-peptide skin-care line and also offers compounded GHK-Cu through a prescriber is running two regulated businesses, and each needs its own review; see peptide law for clinics and med spas.
Common questions
Is GHK-Cu FDA-approved?
No. GHK-Cu is not an FDA-approved drug and is not on the 503A bulks list. Since May 14, 2026, non-injectable GHK-Cu is in Category 1 of the FDA's interim 503A policy, which is enforcement policy, not approval.
Are copper peptide serums legal?
Yes, as cosmetics, when they are sold for appearance only. Cosmetics other than color additives need no FDA approval. Claims to restore hair growth, regenerate cells or treat a condition can make the product a drug.
Can a pharmacy compound GHK-Cu?
A 503A pharmacy may compound GHK-Cu other than in injectable forms under the conditions of the FDA's interim policy, because the FDA put it back in Category 1 on May 14, 2026. Injectable GHK-Cu is not covered.
Can a clinic offer GHK-Cu injections?
As of November 2, 2026 we have found no federal policy that covers compounding injectable GHK-Cu. It is outside the Category 1 entry, it is in the FDA's withdrawn table with a safety statement, and HHS's October 2026 peptide policy does not list it.
Is GHK-Cu covered by the October 2026 HHS peptide policy?
No. HHS's draft policy lists six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500.
Will GHK-Cu be added to the 503A bulks list?
The FDA says it intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027. Adding it to the list would then take rulemaking.
Update log
- November 2, 2026. Published. The FDA's 503A category list (May 14, 2026), 503A page, safety-risk page and cosmetics pages, the Federal Register notice, the HHS policy's Appendix A and the Justice Department release checked November 2, 2026.
Sources
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list updated May 14, 2026)
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A (current as of May 14, 2026)
- FDA, Certain Bulk Drug Substances That May Present Significant Safety Risks (current as of April 22, 2026)
- FDA, 503B category list (updated March 21, 2025)
- 21 U.S.C. 321 (definitions: drug, cosmetic)
- 21 U.S.C. 353a (section 503A)
- 21 U.S.C. 355 (new drugs)
- 21 CFR 216.23 (503A bulks list)
- 21 CFR 201.128 (intended use)
- FDA, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) (current as of September 11, 2024)
- FDA Authority Over Cosmetics (current as of November 18, 2025)
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Oct. 30, 2026)
- HHS, the policy with Appendix A (peptides covered), hhs.gov PDF (read November 2, 2026)
- FDA warning letter, Tailor Made Compounding (April 1, 2020)
- U.S. Attorney's Office, D. Utah, physician indicted over misbranded drugs from China (April 1, 2026)
- 21 NCAC 46 .2801 (North Carolina compounding rule; Cornell LII copy)
Related
Selling a copper-peptide line, or adding GHK-Cu to a practice?
DPS Law advises clinics, med spas, pharmacies and brands on North Carolina and federal drug, compounding and cosmetic labeling law. For another state's rules, talk to a lawyer licensed in that state.